Potent and selective inhibition of CDK7 by novel covalent inhibitors

被引：0
|
作者：
Satyam, L. [1 ]
Poddutoori, R. [1 ]
Mukherjee, S. [1 ]
Marappan, S. [1 ]
Gopinath, S. [1 ]
Pothuganti, M. [1 ]
Nayak, S. [1 ]
Kaza, L. [1 ]
Nandish, C. [1 ]
Amith, A. [1 ]
Ravindra, M. [1 ]
Nagaraju, A. [1 ]
Antony, T. [1 ]
Pandit, C. [1 ]
Chelur, S. [1 ]
Daginakatte, G. [1 ]
Samajdar, S. [1 ]
Ramachandra, M. [1 ]
机构：
[1] Aurigene Discovery Technol Ltd, Preclin Biol, Bangalore, Karnataka, India
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32978-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
386
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [31] CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
    Diab, Sarah
    Yu, Mingfeng
    Wang, Shudong
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (14) : 7458 - 7474
  • [32] Starving multiple myeloma cells via CDK7 inhibition
    Sacco, Antonio
    Roccaro, Aldo M.
    BLOOD, 2023, 141 (23) : 2787 - 2788
  • [33] Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors
    Liu Tao
    Sun Mao-Tang
    Dong Xiao-Wu
    Ren Xin
    Yang Xin
    Du Li-Lin
    Hu Yong-Zhou
    ACTA PHYSICO-CHIMICA SINICA, 2009, 25 (10) : 2107 - 2112
  • [34] CDK7 inhibition suppresses MYC-dependent cancer
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2015, 14 (1) : 16 - 16
  • [35] Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model
    Poddutoori, Ramulu
    Rajagopalan, Sujatha
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Sivakumar, Sasirekha
    Nayak, Shilpa S.
    Ravindra, M., V
    Murtuza, Hadianawala
    Devaraja, T. S.
    Kondela, Srinivas
    Tgore, Suraj
    Dhudashiya, Amit A.
    Charamanna, K. B.
    Antony, Thomas
    Daginakatte, Girish
    Giri, Sanjeev
    Chelur, Shekar
    Ramachandra, Murali
    Pandit, Chetan
    Samajdar, Susanta
    CANCER RESEARCH, 2018, 78 (13)
  • [36] AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7
    Besnard, Jeremy
    Joseph, James
    Bai, Haiyun
    Paveley, Ross A.
    Wang, Tao
    Barbeau, Olivier R.
    Gu, Xiao-Hui
    Bell, Andrew S.
    Somlyay, Mate
    Taubert, Christina
    Boudesco, Christophe
    Vladimer, Gregory
    Aswad, Fred
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods
    Rusina, Polina, V
    Titov, Ilya Yu
    Panova, Maria, V
    Stroylov, Victor S.
    Abdyusheva, Yana R.
    Murlatova, Elizaveta Yu
    Svitanko, Igor, V
    Novikov, Fedor N.
    MENDELEEV COMMUNICATIONS, 2020, 30 (04) : 430 - 432
  • [38] Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
    Guarducci, C.
    Nardone, A.
    Feiglin, A.
    Migliaccio, I.
    Malorni, L.
    Bonechi, M.
    Benelli, M.
    Di Leo, A.
    Hodgson, G.
    Shapiro, G.
    Brown, M.
    Jeselsohn, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation
    Ma, Xinqi
    Kuang, Xielan
    Xia, Qing
    Huang, Zixin
    Fan, Yuting
    Ning, Jie
    Wen, Jiajie
    Zhang, Han
    Yan, Jianhua
    Zhang, Qingjiong
    Shen, Huangxuan
    Long, Chongde
    JOURNAL OF CANCER, 2018, 9 (17): : 3149 - 3155
  • [40] Discovery of Potent and Selective Covalent Inhibitors of JNK
    Zhang, Tinghu
    Inesta-Vaquera, Francisco
    Niepel, Mario
    Zhang, Jianming
    Ficarro, Scott B.
    Machleidt, Thomas
    Xie, Ting
    Marto, Jarrod A.
    Kim, NamDoo
    Sim, Taebo
    Laughlin, John D.
    Park, Hajeung
    LoGrasso, Philip V.
    Patricelli, Matt
    Nomanbhoy, Tyzoon K.
    Sorger, Peter K.
    Alessi, Dario R.
    Gray, Nathanael S.
    CHEMISTRY & BIOLOGY, 2012, 19 (01): : 140 - 154
12345